3.4 | 2-year CIRs for CIN2+ and CIN3+ by 6 months
Figure
S2 shows the CIRs of CIN2+ (a) and CIN3+ (b) by
6 months according to AHPV-GT
positivity status at baseline.
During the 2-year follow-up, 10 patients of the 349 enrolled women
(2.9%) progressed to CIN3+. Forty percent (4/10) of the cases of
progression occurred at the first follow-up, 20.0% (2/10) at the
second, 30.0% (3/10) at the third, and 10.0% (1/10) at the fourth. All
assays showed a similar trend, with consistently higher risk for women
with the HPV 16 genotype as well as higher risk for those with
AHPV-GT-positive genotypes than those with AHPV-GT-negative genotypes
every 6 months. Similar results were observed using a CIN2+ endpoint.
3.5 | 2-year CIRs
for CIN2+ and CIN3+ by baseline AHPV-GT, age at diagnosis and enrolment
cytology status
Figure 1 presents the 2-year CIRs of CIN2+ and CIN3+ by baseline
AHPV-GT, age at diagnosis and enrolment cytology status. The 2-year CIR
of CIN3+ in the group of AHPV-GT-positive women at baseline was
significantly higher than that in the group of AHPV-GT-negative women
(8.6% [95% CI; 2.9–19.0%] vs. 1.7% [95% CI; 0.6–4.0%],P = 0.014), with a CIR ratio of 5.0 (95% CI; 1.5–16.8). In
the ≥25-year-old group, the
2-year CIR of CIN3+ in the group of AHPV-GT-positive women was
significantly higher than that in the group of AHPV-GT-negative women
(10.9% [95% CI; 3.6–23.6%] vs. 1.5% [95% CI; 0.4–3.8%],P = 0.002). However, there was no significant difference between
the two subgroups in the 21–24-year-old group (8.3% [95% CI;
0.2–38.5%] vs. 0.0% [95% CI; 0.0–14.8%], P = 0.343).
In the two groups of women with NILM and ASC-US/LSIL cytology at
baseline, the 2-year CIRs of CIN3+ were both higher in the
AHPV-GT-positive subgroup at baseline than in the AHPV-GT-negative
subgroup, but there was no significant difference between the two
subgroups (P = 0.536, P = 0.097, respectively). Similar
results were achieved when comparing the 2-year CIRs of CIN2+.